Steroidophobia in dermatology - contemporary problem of the past
- Authors: Dvoryankova E.V.1
-
Affiliations:
- Center of Theoretic Problems of Physical and Chemical Pharmacology, Russian Academy of Sciences
- Issue: Vol 91, No 3 (2015)
- Pages: 131-134
- Section: CLINICAL PRACTICE GUIDELINES
- URL: https://journals.rcsi.science/0042-4609/article/view/116737
- DOI: https://doi.org/10.25208/0042-4609-2015-91-3-131-134
- ID: 116737
Cite item
Full Text
Abstract
About the authors
E. V. Dvoryankova
Center of Theoretic Problems of Physical and Chemical Pharmacology, Russian Academy of Sciences
Author for correspondence.
Email: dvoriankova@mail.ru
Russian Federation
References
- Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142 (5): 931-936.
- Aubert-Wastiaux H., Moret L., Le Rhun A. et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011; 165 (4): 808-814.
- Zuberbier T., Orlow S.J., Paller A.S. et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006; 118 (1): 226-232.
- Rathi S.K., D'Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol 2012; 57 (4): 251-259.
- Rathi S. Abuse of topical steroid as cosmetic cream: A social background of steroid dermatitis. Indian J Dermatol 2006; 51: 154-155.
- Bhat Y.J., Manzoor S., Qayoom S. Steroid-induced rosacea: a clinical study of 200 patients. Indian J Dermatol 2011; 56: 30-32.
- Moret L., Anthoine E., Aubert-Wastiaux H. et al. TOPICOP©: a new scale evaluating topical corticosteroid phobia among atopic dermatitis outpatients and their parents. PLoS One 2013; 8 (10): e76493.
- Huang K.E., Davis S.A., Cantrell J., Feldman S.R. Increasing use of non-traditional vehicles for psoriasis and other inflammatory skin conditions. Dermatol Online J 2014; 20 (9): 10.
- Belousova T.A. Naruzhnaya terapiya allergicheskogo dermatita i ekzemy. Vestn dermatol venerol 2008; 2: 97-103. [Белоусова Т.А. Наружная терапия аллергического дерматита и экземы. Вестн дерматол венерол 2008; 2: 97-103.]
- Perlamutrov Yu.N., Ol'khovskaya K.B., Samtsov A.V. Results of an all-russian multicenter open-label follow-up study «ELLIPS» to evaluate the efficacy, safety and tolerance of treatment with various Forms of Advantan in eczema patients. Vestn Dermatol Venerol 2009; 6: 116-123. [Перламутров Ю.Н., Ольховская К.Б., Самцов А.В. и соавт. Результаты Всероссийского многоцентрового открытого наблюдательного исследования «ЭЛЛИПС» по определению эффективности, безопасности и переносимости лечения больных экземой различными формами препарата Адвантан. Вестн дерматол венерол 2009; 6: 116-123.]
- Fritsch P. Clinical experience with methylprednisolone aceponate (MPA) in eczema. J Dermatol Treat 1992; 3 (2): 17-19.
- Kecskes A., Heger-Mahn D., Kleine-Kuhlmann R. et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol 1993; 29: 576-580.
- Zaumseil R.-P., Kecskes A., Tauber U. et al. Methylprednisolone aceponate (MPA) - a new therapeutic for eczema: a pharmacological overview. J Dermatol Treat 1992; 3 (Suppl 2): 3-7.
- Klinicheskaya allergologiya detskogo vozrasta s neotlozhnymi sostoyaniyami. Rukovodstvo dlya vrachey pod redaktsiey Balabolkina I.I., Bulgakovoy A.V. M: MIA 201; 264. [Клиническая аллергология детского возраста с неотложными состояниями. Руководство для врачей под редакцией И.И. Балаболкина, А.В. Булгаковой. М: МИА 2011; 264.]
Supplementary files
